StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Employer - Self Funded Plans

<< Previous

Bullboard Posts

Next >>

Post by LithLoveron Dec 02, 2022 2:51pm

229 Views

Post# 35147300

Employer - Self Funded Plans

LinkedIn a few hours ago:
StageZero Life Sciences Ltd. (TSX: SZLS)

It’s well known that cancer survival rates improve with early detection. But did you know that treating late-stage cancer is almost double the cost of treating early-stage cancer? If you’re an employer looking to mitigate the high cost of catastrophic cancer claims to your self-funded plan, contact us to learn more about our cancer prevention and early detection programs.

Learn more at https://lnkd.in/eyk7Hc6W